Palo Alto Health Sciences Obtains FDA-Clearance For Freespira In Treating PTSD

Palo Alto Health Sciences, Inc. (PAHS) recently announced it has obtained U.S. Food and Drug Administration (FDA) clearance for Freespira. Freespira is PAHS’s flagship digital therapeutic, and intended for the treatment of post-traumatic stress disorder (PTSD).

Studies of Freespira have shown that most people experience a significant reduction—or complete elimination—of panic attacks after completing treatments of it. This is significant, as 7-8% of Americans are estimated to receive a diagnosis of PTSD each year. Recent studies have demonstrated satisfaction rates of 90% in individuals using Freespira after six months of post-treatment. PAHS cites . . .